Montelucaste Tecnigen (Montelukast)

Montelukast, the active ingredient in Montelucaste Tecnigen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma and allergic rhinitis in adults and children, helping to control symptoms and reduce flare‑ups. GNH USA supplies Montelucaste Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways that contribute to airway inflammation and nasal symptoms. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and runny nose. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of queasiness that may lead to vomiting. - Dizziness: transient light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Allergic reactions: including rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following safety measures. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Assess liver function: periodic testing is advised in patients with hepatic disease. - Use caution in severe asthma: ensure patients have a rescue inhaler. - Review concomitant medications: check for potential drug interactions. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower montelukast levels. - Phenobarbital: can decrease therapeutic effect. - St. John’s wort: may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for additive neuropsychiatric effects. - Antifungal azoles (ketoconazole): may increase plasma concentrations. - Warfarin: monitor INR for possible anticoagulant effect changes.